Gülcan Akyüz Yücel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gülcan Akyüz Yücel has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ali Cansu
Department of Pediatric Neurology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
1 shared publication - Almala Pinar Ergenekon
Division of Pediatric Pulmonology, Marmara University School of Medicine, İstanbul, Türkiye
1 shared publication - Beril Dilber
Department of Pediatric Neurology, Karadeniz Technical University, Trabzon, Turkey
1 shared publication - Betül Diler Durgut
Giresun University
1 shared publication Betül Kiliç
Department of Pediatric Neurology, Faculty of Medicine, Medipol University Hospital, Istanbul, Türkiye
1 shared publication- Bilgihan Bıkmazer
Marmara University Training and Research Hospital, Pediatric Neurology Clinic, Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
Therapeutic Plasma Exchange in Critically Ill Children with Neuroimmunological Disorders: A Single-Center Cohort Study
Background: Therapeutic plasma exchange (TPE) is increasingly used in pediatric neuroimmunological disorders; however, evidence remains limited, particularly for rare neuroinflammatory and infection-triggered encephalopathy syndromes. We aimed to describe the clinical characteristics, treatment patterns, and outcomes of critically ill children who underwent TPE for neuroimmunological disorders in a tertiary pediatric intensive care unit. Methods: This retrospective observational study included consecutive patients younger than 18 years who received TPE for neuroimmunological disorders between September 2020 and December 2025. Demographic characteristics, disease spectrum, TPE indications, treatment details, neuroimaging findings, cerebrospinal fluid (CSF) characteristics, and clinical outcomes were reviewed. Neurological outcome at hospital discharge was assessed using the Pediatric Cerebral Performance Category (PCPC) score. Results: Twenty-two patients were included. The median age was 104 months (IQR, 62.3–151.8), and 50% were female. Guillain–Barré syndrome (GBS) was the most common diagnosis (n = 6), followed by autoimmune encephalitis (n = 6), infection-triggered encephalopathy syndrome (ITES)/acute necrotizing encephalopathy (ANE) spectrum disorders (n = 4), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (n = 3), acute disseminated encephalomyelitis (ADEM) (n = 2), and mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) (n = 1). The median interval from symptom onset to TPE initiation was 9 days (IQR, 6–13), and patients underwent a median of 7 TPE sessions (IQR, 5–10.5). Nine patients (40.9%) required invasive mechanical ventilation and four (18.1%) required vasoactive support. Favorable neurological outcomes at hospital discharge were observed in 63.6% of patients, whereas 36.4% had unfavorable neurological outcomes. Mortality occurred in 13.6% of patients and was confined to severe encephalopathic syndromes. No major TPE-related complications were observed. Conclusions: TPE was used across a heterogeneous spectrum of pediatric neuroimmunological disorders, including both guideline-supported and non-standard indications. Approximately one-quarter of patients had conditions not specifically addressed in current ASFA recommendations, highlighting the gap between real-world clinical practice and the available evidence base. Multicenter studies are needed to better define the optimal role, timing, and patient selection criteria for TPE in pediatric neuroimmunology.
Open AccessTherapeutic Plasma Exchange in Critically Ill Children with Neuroimmunological Disorders: A Single-Center Cohort Study
Background: Therapeutic plasma exchange (TPE) is increasingly used in pediatric neuroimmunological disorders; however, evidence remains limited, particularly for rare neuroinflammatory and infection-triggered encephalopathy syndromes. We aimed to describe the clinical characteristics, treatment patterns, and outcomes of critically ill children who underwent TPE for neuroimmunological disorders in a tertiary pediatric intensive care unit. Methods: This retrospective observational study included consecutive patients younger than 18 years who received TPE for neuroimmunological disorders between September 2020 and December 2025. Demographic characteristics, disease spectrum, TPE indications, treatment details, neuroimaging findings, cerebrospinal fluid (CSF) characteristics, and clinical outcomes were reviewed. Neurological outcome at hospital discharge was assessed using the Pediatric Cerebral Performance Category (PCPC) score. Results: Twenty-two patients were included. The median age was 104 months (IQR, 62.3–151.8), and 50% were female. Guillain–Barré syndrome (GBS) was the most common diagnosis (n = 6), followed by autoimmune encephalitis (n = 6), infection-triggered encephalopathy syndrome (ITES)/acute necrotizing encephalopathy (ANE) spectrum disorders (n = 4), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (n = 3), acute disseminated encephalomyelitis (ADEM) (n = 2), and mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) (n = 1). The median interval from symptom onset to TPE initiation was 9 days (IQR, 6–13), and patients underwent a median of 7 TPE sessions (IQR, 5–10.5). Nine patients (40.9%) required invasive mechanical ventilation and four (18.1%) required vasoactive support. Favorable neurological outcomes at hospital discharge were observed in 63.6% of patients, whereas 36.4% had unfavorable neurological outcomes. Mortality occurred in 13.6% of patients and was confined to severe encephalopathic syndromes. No major TPE-related complications were observed. Conclusions: TPE was used across a heterogeneous spectrum of pediatric neuroimmunological disorders, including both guideline-supported and non-standard indications. Approximately one-quarter of patients had conditions not specifically addressed in current ASFA recommendations, highlighting the gap between real-world clinical practice and the available evidence base. Multicenter studies are needed to better define the optimal role, timing, and patient selection criteria for TPE in pediatric neuroimmunology.
- Open Access
Personalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.
Open AccessPersonalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.